GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Spermosens AB (STU:9R5) » Definitions » EV-to-FCF

Spermosens AB (STU:9R5) EV-to-FCF : -0.76 (As of Mar. 03, 2025)


View and export this data going back to 2024. Start your Free Trial

What is Spermosens AB EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Spermosens AB's Enterprise Value is €0.87 Mil. Spermosens AB's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was €-1.14 Mil. Therefore, Spermosens AB's EV-to-FCF for today is -0.76.

The historical rank and industry rank for Spermosens AB's EV-to-FCF or its related term are showing as below:

STU:9R5' s EV-to-FCF Range Over the Past 10 Years
Min: -2.75   Med: 0   Max: 0
Current: -0.76

STU:9R5's EV-to-FCF is ranked worse than
100% of 98 companies
in the Medical Diagnostics & Research industry
Industry Median: 25.87 vs STU:9R5: -0.76

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-03-03), Spermosens AB's stock price is €0.0004. Spermosens AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was €-0.004. Therefore, Spermosens AB's PE Ratio (TTM) for today is At Loss.


Spermosens AB EV-to-FCF Historical Data

The historical data trend for Spermosens AB's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spermosens AB EV-to-FCF Chart

Spermosens AB Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-FCF
Get a 7-Day Free Trial - -11.16 -0.95 -1.45 -0.27

Spermosens AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.45 -1.48 -0.74 -0.44 -0.27

Competitive Comparison of Spermosens AB's EV-to-FCF

For the Diagnostics & Research subindustry, Spermosens AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Spermosens AB's EV-to-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Spermosens AB's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Spermosens AB's EV-to-FCF falls into.



Spermosens AB EV-to-FCF Calculation

Spermosens AB's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=0.868/-1.135
=-0.76

Spermosens AB's current Enterprise Value is €0.87 Mil.
Spermosens AB's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.14 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Spermosens AB  (STU:9R5) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Spermosens AB's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.0004/-0.004
=At Loss

Spermosens AB's share price for today is €0.0004.
Spermosens AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.004.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Spermosens AB EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Spermosens AB's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Spermosens AB Business Description

Traded in Other Exchanges
Address
Scheeletorget 1, Medicon Village, Lund, SWE, 223 81
Spermosens AB is developing a revolutionary platform technology for diagnosing male-factor infertility and directing to the right infertility treatment. It is a developer of medical device products for male infertility, individualizing In Vitro Fertilization (IVF) diagnostics and treatment creating a new standard for faster and safer IVF treatments.

Spermosens AB Headlines

No Headlines